Quebec government clinical experts say there isn't enough evidence to recommend widespread use of the popular gout medication to treat COVID-19 patients, dampening hopes the drug could be a short-term tool to reduce hospitalizations and deaths.
Little evidence that colchicine benefits COVID-19 patients, Quebec advisory panel finds
Post a Comment